SCHEMBL1401723

SCHEMBL1401723

COc1cc2ncnc(Oc3ccc4[nH]ccc4c3F)c2cc1OC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.54
PIK3CA P42336 2/20 0.54
PIK3CB P42338 2/20 0.54
PIK3CG P48736 2/20 0.54
BRAF P15056 2/20 0.51
GPR119 Q8TDV5 1/20 0.48
PDE4B Q07343 3/20 0.47
PDE4A P27815 2/20 0.47
PDE4C Q08493 2/20 0.47
PDE4D Q08499 2/20 0.47
KDR P35968 2/20 0.44
EGFR P00533 7/20 0.44
ERBB2 P04626 4/20 0.44
RIPK2 O43353 2/20 0.44
RET P07949 2/20 0.44
MET P08581 2/20 0.44
EPHB4 P54760 2/20 0.44
BTK Q06187 2/20 0.44
EPHB2 P29323 1/20 0.44
TEC P42680 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1401725 0.90 PIK3CD (0.48) PIK3CDPIK3CAPIK3CBPIK3CGBRAF
SCHEMBL1401697 0.90 PIK3CD (0.51) PIK3CDPIK3CAPIK3CBPIK3CGKDR
SCHEMBL662774 0.89 KDR (0.57) PIK3CDPIK3CAPIK3CBPIK3CGBRAF
SCHEMBL1401670 0.83 EGFR (0.56) KDREGFRERBB2RIPK2RET
SCHEMBL1401658 0.82 KDR (0.48) BRAFKDREGFRERBB2RIPK2
SCHEMBL1401676 0.80 KDR (0.48) PIK3CDPIK3CAPIK3CBPIK3CGKDR
SCHEMBL665930 0.80 BRAF (0.55) PIK3CDPIK3CAPIK3CBPIK3CGBRAF
SCHEMBL1401690 0.79 KDR (0.59) PIK3CDPIK3CAPIK3CBPIK3CGBRAF
SCHEMBL29111048 0.79 BRAF (0.55) PIK3CDPIK3CAPIK3CBPIK3CGBRAF
SCHEMBL12369330 0.78 EGFR (0.57) PIK3CDPIK3CAPIK3CBPIK3CGKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293902-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2012-10-23 US disclosed
EP-2292615-A1 Quinazoline compounds AstraZeneca AB (SE) 2011-03-09 EP disclosed
US-20090156821-A1 Quinazoline compounds ASTRAZENECA AB 2009-06-18 US disclosed
US-20080027069-A1 Quinazoline compounds ASTRAZENECA AB 2008-01-31 US disclosed
US-7268230-B2 Quinazoline compounds ASTRAZENECA AB (SE) 2007-09-11 US disclosed
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents ASTRAZENECA AB (SE) 2005-04-21 US disclosed
EP-1474420-A1 QUINAZOLINE COMPOUNDS Astrazeneca AB (SE) 2004-11-10 EP disclosed
WO-2003064413-A1 QUINAZOLINE COMPOUNDS ASTRAZENECA AB (SE) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085465-A1 Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents VEGFA, FLT4, FLT1 PIK3CD 1529/4885PIK3CA 1278/4885PIK3CB 2112/4885
US-20090156821-A1 Quinazoline compounds VEGFA, FLT4, FLT1 PIK3CD 1331/4885PIK3CA 1090/4885PIK3CB 1895/4885
US-20080027069-A1 Quinazoline compounds VEGFA, FLT4, FLT1 PIK3CD 1331/4885PIK3CA 1090/4885PIK3CB 1895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.